Identification of 5-HT<sub>2A</sub> receptor signaling pathways associated with psychedelic potential.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38102107.
- Also identified by DOI 10.1038/s41467-023-44016-1 and PMC identifier 10724237.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Serotonergic psychedelics possess considerable therapeutic potential. Although 5-HT<sub>2A</sub> receptor activation mediates psychedelic effects, prototypical psychedelics activate both 5-HT<sub>2A</sub>-Gq/11 and β-arrestin2 transducers, making their respective roles unclear. To elucidate this, we develop a series of 5-HT<sub>2A</sub>-selective ligands with varying Gq efficacies, including β-arrestin-biased ligands. We show that 5-HT<sub>2A</sub>-Gq but not 5-HT<sub>2A</sub>-β-arrestin2 recruitment efficacy predicts psychedelic potential, assessed using head-twitch response (HTR) magnitude in male mice. We further show that disrupting Gq-PLC signaling attenuates the HTR and a threshold level of Gq activation is required to induce psychedelic-like effects, consistent with the fact that certain 5-HT<sub>2A</sub> partial agonists (e.g., lisuride) are non-psychedelic. Understanding the role of 5-HT<sub>2A</sub> Gq-efficacy in psychedelic-like psychopharmacology permits rational development of non-psychedelic 5-HT<sub>2A</sub> agonists. We also demonstrate that β-arrestin-biased 5-HT<sub>2A</sub> receptor agonists block psychedelic effects and induce receptor downregulation and tachyphylaxis. Overall, 5-HT<sub>2A</sub> receptor Gq-signaling can be fine-tuned to generate ligands distinct from classical psychedelics.
Medical subject headings
- Hallucinogens